{"id":10139,"date":"2023-08-29T15:23:32","date_gmt":"2023-08-29T15:23:32","guid":{"rendered":"https:\/\/colorectalcc.wpengine.com\/?p=10139"},"modified":"2023-08-29T15:23:32","modified_gmt":"2023-08-29T15:23:32","slug":"la-fda-approuve-lonsurf-plus-bevacizumab-pour-le-traitement-du-cancer-colorectal-metastatique","status":"publish","type":"post","link":"https:\/\/www.colorectalcancercanada.com\/fr\/blogue\/la-fda-approuve-lonsurf-plus-bevacizumab-pour-le-traitement-du-cancer-colorectal-metastatique\/","title":{"rendered":"La FDA approuve Lonsurf plus bevacizumab pour le traitement du cancer colorectal m\u00e9tastatique"},"content":{"rendered":"<p><strong>Ao\u00fbt 2023<\/strong><\/p>\n<p>La Food and Drug Administration (FDA) des \u00c9tats-Unis <a href=\"https:\/\/www.prnewswire.com\/news-releases\/fda-approves-lonsurf-trifluridinetipiracil-in-combination-with-bevacizumab-for-adult-patients-with-metastatic-colorectal-cancer-mcrc-301892077.html\" target=\"_blank\" rel=\"noopener\">a approuv\u00e9<\/a> l&rsquo;association th\u00e9rapeutique trifluridine\/tipiracil (Lonsurf) et bevacizumab pour le traitement des adultes atteints d&rsquo;un cancer colorectal m\u00e9tastatique (CCRm) ayant re\u00e7u un traitement ant\u00e9rieur \u00e0 base de 5-FU-, oxaliplatine et irinot\u00e9can (comme FOLFOX et FOLFIRI), une th\u00e9rapie cibl\u00e9e anti-VEGF (comme le bevacizumab) et, dans le cas o\u00f9 ils sont de type RAS sauvage, une th\u00e9rapie anti-EGFR tel que le panitumumab ou le cetuximab. Lonsurf est approuv\u00e9 comme traitement en monoth\u00e9rapie pour les patients atteints de mCRC ayant d\u00e9j\u00e0 trait\u00e9s.<\/p>\n<p>L&rsquo;autorisation de la FDA repose sur les r\u00e9sultats de l&rsquo;essai de phase III SUNLIGHT. Cet essai a compar\u00e9 Lonsurf associ\u00e9 au bevacizumab versus le Lonsurf seul (sans association \u00e0 un autre m\u00e9dicament) pour les patients atteints de mCRC ayant re\u00e7u au maximum deux lignes de chimioth\u00e9rapie ant\u00e9rieures et pr\u00e9sentant une progression de la maladie ou une r\u00e9sistance au traitement (c&rsquo;est-\u00e0-dire que le traitement a cess\u00e9 d&rsquo;agir). La survie m\u00e9diane sans progression \u00e9tait de 5,6 mois pour le groupe ayant re\u00e7u le traitemnt en association comparativement \u00e0 2,4 mois dans celui ayant re\u00e7u le Lonsurf seul. La survie m\u00e9diane globale a \u00e9t\u00e9 de 10,8 mois, contre 7,5 mois dans le groupe trait\u00e9 par l&rsquo;association et dans le groupe trait\u00e9 par Lonsurf seul, respectivement.<\/p>\n<p>Au Canada, Lonsurf est approuv\u00e9 par Sant\u00e9 Canada pour le traitement du mCRC r\u00e9fractaire. Il n&rsquo;est actuellement rembours\u00e9 que dans la province de Qu\u00e9bec. Lonsurf en association avec le bevacizumab n&rsquo;est actuellement disponible que dans le cadre d&rsquo;essais cliniques.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ao\u00fbt 2023 La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 l&rsquo;association th\u00e9rapeutique trifluridine\/tipiracil (Lonsurf) et bevacizumab pour le traitement des adultes atteints d&rsquo;un cancer colorectal m\u00e9tastatique (CCRm) ayant re\u00e7u un traitement ant\u00e9rieur \u00e0 base de 5-FU-, oxaliplatine et irinot\u00e9can (comme FOLFOX et FOLFIRI), une th\u00e9rapie cibl\u00e9e anti-VEGF (comme <a href=\"https:\/\/www.colorectalcancercanada.com\/fr\/blogue\/la-fda-approuve-lonsurf-plus-bevacizumab-pour-le-traitement-du-cancer-colorectal-metastatique\/\">&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":10132,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[42],"tags":[],"class_list":["post-10139","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogue"],"_links":{"self":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/10139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/comments?post=10139"}],"version-history":[{"count":0,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/10139\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media\/10132"}],"wp:attachment":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media?parent=10139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/categories?post=10139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/tags?post=10139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}